Med Biogene (MBI) Stock Price, News & Analysis

Company Overview

Med BioGene Inc., a life science company, focuses on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. Its products include the GeneFx Lung, a gene expression-based test for early-stage non-small-cell lung cancer that assists in identifying patients for adjuvant chemotherapy. The company has a collaboration agreement with the University Health Network in Toronto. Med BioGene Inc. was founded in 2002 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: C$0.05 to C$0.05
• 50-Day Range: C$0.05 to C$0.05
• 52-Week Range: C$0.02 to C$0.08
• Volume: 2,000 shs
• Average Volume: 29,135 shs
• Market Capitalization: C$596.61 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MBI Stock Analysis - Frequently Asked Questions

How have MBI shares performed this year?

Med Biogene's stock was trading at C$0.05 at the beginning of 2025. Since then, MBI shares have increased by 0.0% and is now trading at C$0.05.
View the best growth stocks for 2025 here.

How do I buy shares of Med Biogene?

Shares of MBI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: Insurance
• Current Symbol: CVE:MBI
• CIK: N/A
• Web: www.medbiogene.com
• Phone: +1-604-7327332
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.95
• Quick Ratio: 0.92

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.01 per share
• Price / Cash Flow: 3.46
• Book Value: C$0.00 per share
• Price / Book: -45.00

Miscellaneous

• Outstanding Shares: 13,258,000
• Free Float: N/A
• Market Cap: C$596.61 thousand
• Optionable: Not Optionable
• Beta: N/A